New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
07:20 EDTICPTIntercept data should be positive catalyst for shares, says Oppenheimer
Oppenheimer predicts that top-line data for Intercept's Phase 2 FLINT study in NASH, expected to be released in July, will be a positive catalyst for the stock. The firm thinks that the risk/reward ratio for the stock heading into the data release should be attractive as long as expectations remain modest. It keeps a $499 price target and Outperform rating on the stock.
News For ICPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 19, 2015
16:31 EDTICPTIntercept promotes Lisa Bright to Chief Commercial & Corporate Affairs Officer
Intercept Pharmaceuticals announced that Lisa Bright has been promoted to the newly-created position of Chief Commercial and Corporate Affairs Officer. Bright joined Intercept last year from Gilead Sciences where her leadership of the European launch of Sovaldi for the treatment of chronic hepatitis C contributed to the most successful product launch in pharmaceutical history.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use